drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Gene-modified natural killer cells engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on myeloma cells, activating NK cytotoxic pathways to kill malignant plasma cells.
nci_thesaurus_concept_id
C184309
nci_thesaurus_definition
A preparation of umbilical cord blood (CB)-derived natural killer cells (NKs) expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-BCMA CAR-NK cells recognize, bind to and induce selective cytotoxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ex vivo–engineered natural killer cells expressing a chimeric antigen receptor specific for BCMA (TNFRSF17) recognize and bind BCMA on malignant plasma cells, triggering NK activation and targeted cytotoxicity via perforin/granzyme release and cytokine-mediated killing, independent of MHC.
drug_name
Anti-BCMA CAR-NK cells
nct_id_drug_ref
NCT06242249